When is the best time to give carbetocin to stop postpartum bleeding?
NCT ID NCT06776926
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed trial studied 200 first-time mothers having a normal vaginal delivery to find the best time to give carbetocin, a drug that prevents severe bleeding after childbirth. Researchers compared giving the drug at different times to see which reduced bleeding, side effects, and the need for extra medications. The goal is to improve safety during childbirth.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- carbetocin
- What this could lead to
- If successful, this could help doctors choose the best time to give carbetocin to prevent dangerous bleeding after childbirth.
- What could go wrong
- This is a small, completed trial with 200 participants, so results may not apply to all women. The timing difference may not be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
200 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Feb 2025
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Singleton pregnancy * Vaginal delivery at or beyond 38 weeks of gestation * Primipar Exclusion Criteria: * Multiparity * Contraindications to carbetocin use (e.g., pre-existing hypertension, pre-eclampsia,asthma, cardiac, renal, or liver disease) * High-risk factors for primary postpartum hemorrhage, including grand multiparity,presence of uterine fibroids, or a need for prophylactic oxytocin infusion * Anemia or * body mass index (BMI) over 35 * Baby weight over 4000 grams * Comorbidities or chronic diseases * History of curettage * Use of propess or oxytocin during labor
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carbetocin are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kartal Dr Lutfi Kirdar City Hospital
Istanbul, Istanbul, 34880, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a slower oxytocin infusion prevent dangerous blood pressure drops in C-Sections?
- A 12-minute video could save new mothers' lives – can it teach them to spot danger?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Medical glue vs. internal bleeding: a new hope?
- Which drug stops Post-Birth bleeding better? a Head-to-Head test
- Could a simple calcium injection prevent dangerous bleeding after childbirth?